For the Inventor, By the Inventor

Enter assignee name

Princeton, NJ, United States of America

Advaxis, Inc.

USPTO Granted Patents = 20

% Expired Patents = 20.0

EPO Patents = 4

Forward Citations = 188

Loading Chart...

Loading Chart...

19 inventors (with patents filed for the assignee):

Anu Wallecha (10 out of 10 patents)

Yvonne Paterson (9 out of 45 patents)

Vafa Shahabi (7 out of 7 patents)

4. John Rothman (6 out of 23 patents)

5. Robert Petit (6 out of 6 patents)

6. Paulo Cesar Maciag (4 out of 13 patents)

7. Reshma Singh (3 out of 15 patents)

8. Michael F Princiotta (3 out of 3 patents)

9. Melissa Gosse (2 out of 3 patents)

10. David Fela (2 out of 2 patents)

11. Mike Grace (2 out of 2 patents)

12. Matthew Seavey (2 out of 11 patents)

13. Donald A Harn, Jr (2 out of 7 patents)

14. Nicola Mason (1 out of 6 patents)

15. Rodolfo Fleury Perini (1 out of 3 patents)

20 patents: Sort by Forward Citations

1. 12239738 - Compositions and methods for lyophilization of bacteria or listeria strains (2025-03-04),

2. 11897927 - Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof (2024-02-13),

3. 11702664 - Listeria-based compositions comprising a peptide minigene expression system and methods of use thereof (2023-07-18),

4. 11446369 - Compositions and methods comprising KLK3 or FOLH1 antigen (2022-09-20),

5. 11179339 - Compositions and methods for lyophilization of bacteria or listeria strains (2021-11-23),

6. 10900044 - Listeria-based compositions comprising a peptide minigene expression system and methods of use thereof (2021-01-26),

7. 10258679 - [object Object] (2019-04-16),

8. 10143734 - Biomarker directed multi-target immunotherapy (2018-12-04),

9. 10064898 - Listeria-based adjuvants (2018-09-04),

10. 10058599 - [object Object] (2018-08-28),

11. 9907849 - Combination of a PD-1 antagonist and a listeria-based vaccine for treating prostate cancer (2018-03-06),

12. 9650639 - Dual delivery system for heterologous antigens (2017-05-16),

13. 9644212 - Dual delivery system for heterologous antigens (2017-05-09),

14. 9549973 - Compositions and methods comprising KLK3 or FOLH1 antigen (2017-01-24),

15. 9499602 - Non-hemolytic LLO fusion proteins and methods of utilizing same (2016-11-22),

Company Overview

Advaxis, Inc. is a biotechnology company based in Princeton, NJ, specializing in the development of innovative immunotherapies for cancer treatment. The company focuses on harnessing the power of the immune system to target and destroy cancer cells, utilizing its proprietary Lm Technology platform. Advaxis aims to create therapies that are both effective and safe, addressing various types of cancers through its research and development efforts in the field of immuno-oncology.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

20 Patents

#45 in Princeton, NJ

#619 in New Jersey

#16,382 in US

#31,233 in the World

Princeton, NJ, United States of America

Advaxis, Inc.

Forward Citations = 188

19 inventors:

Anu Wallecha (10 out of 10 patents)

Yvonne Paterson (9 out of 45 patents)

Vafa Shahabi (7 out of 7 patents)

4. John Rothman (6 out of 23 patents)

5. Robert Petit (6 out of 6 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Advaxis, Inc.. Retrieved from https://idiyas.com/company/advaxis

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…